인쇄하기
취소

Daewoong Pharmaceutical acquires cGMP approval of Nabota factory from US FDA

Published: 2018-05-18 16:23:45
Updated: 2018-05-18 16:23:45

Daewoong Pharmaceutical(CEO Seung-Ho Jeon) received an establishment inspection report(EIR) which mentioned approval for the Nabota(prabotulinumtoxin A, DWP-450) manufacturing facility from the US Food and Drug Administration(FDA). Thus, Daewoong Pharmaceutical is now prepared to acquire approval of Nabota, a self-developed botulinum toxin product, from the US FDA.

As part of the evaluation pr...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.